Standard
Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria. / Baumann, Katrine; Jørgensen, Astrid Helene Ravn; Sørensen, Jennifer Astrup; Zhang, Ditte Georgina; Ghazanfar, Misbah Noshela; Skov, Per Stahl; Woetmann, Anders; Vestergaard, Christian; Maurer, Marcus; Thomsen, Simon Francis.
In:
Clinical and Experimental Allergy, Vol. 53, No. 12, 2023, p. 1318-1321.
Research output: Contribution to journal › Letter › Research › peer-review
Harvard
Baumann, K, Jørgensen, AHR, Sørensen, JA, Zhang, DG, Ghazanfar, MN, Skov, PS
, Woetmann, A, Vestergaard, C, Maurer, M
& Thomsen, SF 2023, '
Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria',
Clinical and Experimental Allergy, vol. 53, no. 12, pp. 1318-1321.
https://doi.org/10.1111/cea.14402
APA
Baumann, K., Jørgensen, A. H. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S.
, Woetmann, A., Vestergaard, C., Maurer, M.
, & Thomsen, S. F. (2023).
Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria.
Clinical and Experimental Allergy,
53(12), 1318-1321.
https://doi.org/10.1111/cea.14402
Vancouver
Baumann K, Jørgensen AHR, Sørensen JA, Zhang DG, Ghazanfar MN, Skov PS et al.
Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria.
Clinical and Experimental Allergy. 2023;53(12):1318-1321.
https://doi.org/10.1111/cea.14402
Author
Baumann, Katrine ; Jørgensen, Astrid Helene Ravn ; Sørensen, Jennifer Astrup ; Zhang, Ditte Georgina ; Ghazanfar, Misbah Noshela ; Skov, Per Stahl ; Woetmann, Anders ; Vestergaard, Christian ; Maurer, Marcus ; Thomsen, Simon Francis. / Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria. In: Clinical and Experimental Allergy. 2023 ; Vol. 53, No. 12. pp. 1318-1321.
Bibtex
@article{bccea43132444c238478e7028b7410d2,
title = "Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria",
author = "Katrine Baumann and J{\o}rgensen, {Astrid Helene Ravn} and S{\o}rensen, {Jennifer Astrup} and Zhang, {Ditte Georgina} and Ghazanfar, {Misbah Noshela} and Skov, {Per Stahl} and Anders Woetmann and Christian Vestergaard and Marcus Maurer and Thomsen, {Simon Francis}",
note = "Funding Information: Katrine Baumann was supported by the BRIDGE—Translational Excellence Programme ( bridge.ku.dk ) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation. Grant agreement no. NNF20SA0064340 (2021 fellows). This study benefitted from the GALEN network of Urticaria Centers of Reference and Excellence (UCAREs, https://ga2len‐ucare.com/ ). 2 ",
year = "2023",
doi = "10.1111/cea.14402",
language = "English",
volume = "53",
pages = "1318--1321",
journal = "Clinical Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "12",
}
RIS
TY - JOUR
T1 - Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria
AU - Baumann, Katrine
AU - Jørgensen, Astrid Helene Ravn
AU - Sørensen, Jennifer Astrup
AU - Zhang, Ditte Georgina
AU - Ghazanfar, Misbah Noshela
AU - Skov, Per Stahl
AU - Woetmann, Anders
AU - Vestergaard, Christian
AU - Maurer, Marcus
AU - Thomsen, Simon Francis
N1 - Funding Information:
Katrine Baumann was supported by the BRIDGE—Translational Excellence Programme ( bridge.ku.dk ) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation. Grant agreement no. NNF20SA0064340 (2021 fellows). This study benefitted from the GALEN network of Urticaria Centers of Reference and Excellence (UCAREs, https://ga2len‐ucare.com/ ). 2
PY - 2023
Y1 - 2023
U2 - 10.1111/cea.14402
DO - 10.1111/cea.14402
M3 - Letter
C2 - 37771063
AN - SCOPUS:85173983055
VL - 53
SP - 1318
EP - 1321
JO - Clinical Allergy
JF - Clinical Allergy
SN - 0954-7894
IS - 12
ER -
